Testosterone Cream for Men

Start here, because the search term is misleading. FDA's own listing of approved testosterone formulations covers topical gel, transdermal patch, buccal system and injection, with no cream on it. So anything sold to you as a testosterone cream in the United States was mixed by a compounding pharmacy. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach you. That is not a reason to panic, but it is a different regulatory footing from the gel a pharmacy stocks off the shelf.

The potency question is not theoretical either. In work cited by the American Urological Association testosterone deficiency guideline, ten pharmacies each filled two prescriptions for 50 mg of compounded testosterone a month apart, and only 50% of the first batch and 30% of the second landed within 20% of the prescribed dose. One sample contained only minimal amounts of testosterone. That same guideline recommends prescribing a commercially manufactured testosterone product rather than a compounded one where possible.

What is actually approved is narrower than the marketing suggests. Testosterone gel comes as a 1% formulation started at 50 mg per day and a 1.62% metered pump delivering 20.25 mg of testosterone in 1.25 g of gel per actuation. There is also a 2% topical solution delivering 30 mg per pump actuation into the armpit. All are Schedule III. Which one a clinician chooses changes the dose, the application site and the monitoring schedule.

Topical testosterone is not absorbed the way a tablet is. Approximately 10% of the testosterone applied to the skin surface reaches the systemic circulation, and the remainder sits in the outer skin layers, which act as a reservoir releasing hormone across the day. In one 1% gel study, serum testosterone rose within 30 minutes of the first application and eight of nine men were inside the normal range by four hours. Absorption then continues for the entire 24-hour dosing interval, which is exactly why the timing of your blood draw matters.

The spread between one man and the next is the part worth staring at. On day 30, the average daily concentration on 1% gel at 100 mg was 792 ng/dL with a standard deviation of 294, and at 50 mg it was 566 with a standard deviation of 262.

Two men on an identical dose can therefore sit hundreds of nanograms apart. Occlusion, skin condition and application site all move the number. Nothing about the tube in your hand tells you where you will land.

The flip side of shallow absorption is that it reverses quickly. Once treatment stops, serum testosterone returns to roughly baseline within 48 to 72 hours on the 1.62% gel, and by about the fifth day after the last application on the 1% gel. If a side effect shows up, the exposure ends in days rather than months. That is a genuine advantage of this route over long-acting depot forms, and it is most of what daily dosing buys you.

Every approved testosterone gel carries a boxed warning headed SECONDARY EXPOSURE TO TESTOSTERONE. It is unusual among boxed warnings because the harm falls on somebody who never took the drug. The label reports postmarketing cases of virilization in children, with signs including enlargement of the penis or clitoris, development of pubic hair, increased erections and libido, aggressive behavior and advanced bone age. Most regressed once exposure stopped. In a few cases enlarged genitalia did not fully return to age-appropriate size and bone age stayed modestly ahead of chronological age.

The transfer numbers come from the label's own pharmacokinetic studies rather than from speculation. After direct skin-to-skin contact with an uncovered 1.62% gel application site, mean testosterone Cavg and Cmax in female partners increased by 280% and 267%. In a 1% gel study, 38 couples had daily 15-minute sessions of vigorous skin contact, and every unprotected female partner reached a serum testosterone above twice her baseline at some point.

This is not a rare edge case. It is what the route does when the precautions are skipped.

Case reports put faces on it. Two pre-pubertal children, a 21-month-old boy and a girl aged three years and eight months, were referred for pubic hair and genital development after passive transfer from fathers using topical testosterone gel. Both fathers applied gel to their arms and chest before bed, and both children often slept in the parents' bed. Levels returned to normal pre-pubertal values once exposure ended. The AUA rates discussing transfer risk with anyone using a testosterone gel or cream as a strong, Grade A recommendation.

The label instructions are short and specific: wash your hands immediately with soap and water after applying, cover the site with clothing once the gel has dried, and wash the site thoroughly before any situation where skin-to-skin contact is anticipated. Each has a measured effect. In the transfer study where the site was covered by a t-shirt two hours after application, partner Cavg and Cmax rose by 6% and 11% rather than 280% and 267%. In the 1% gel couples study, a shirt over the site prevented transfer completely.

Washing is the other lever, and it costs you less than most men assume. In a crossover study in 24 hypogonadal men on 81 mg of 1.62% gel, showering with soap and water at 2 or 6 hours after application reduced mean Cavg by 13% and 12%, and showering at 10 hours had no effect on bioavailability at all. A shower before contact is cheap insurance. Fabric carries the hormone too, so a shirt worn all day is a barrier that later becomes a source if somebody else handles it.

If you live with a young child or a pregnant partner, treat these rules as the condition of using this route rather than as general advice. Watch for inappropriate changes in genital size, new pubic hair or changed libido in a child, and for new acne, changed body hair distribution or other virilization in an adult woman in the household. The label instruction is to stop the gel and get the cause of virilization identified rather than wait to see whether it settles.

Each topical has its own map, and the maps contradict each other. The 1.62% gel goes on clean, dry, intact skin of the shoulders and upper arms, and explicitly not the abdomen, genitals, chest, armpits or knees. The 1% gel goes on the shoulders and upper arms and/or abdomen, and not the genitals, chest, armpits, knees or back. The 2% solution goes only into the axilla, one actuation of 30 mg to each armpit, and its own label states that its application site and dose are not interchangeable with other topical testosterone products.

The site is not arbitrary. Different skin absorbs at different rates, so each approved dose was established at its approved site. There is a transfer consequence as well. In a study where men applied 1.62% gel to the abdomen, a site not approved for that product, and covered it with a t-shirt, partner Cavg and Cmax still rose 43% and 47% on day one and 60% and 58% by day seven. Moving the gel somewhere convenient can defeat the clothing precaution that otherwise works.

One practical consequence follows for compounded creams. If a preparation arrives with no site instruction, or with an instruction borrowed from a different product, that is worth a question before the first application. The approved labels encode years of pharmacokinetic work in one sentence about where to rub it, and they warn on their own face that different topical products can produce different systemic exposure. A compounded cream carries no equivalent study behind its strength, its vehicle or its site.

Before a prescription, the label asks for serum testosterone measured in the morning on at least two separate days, with both results below the normal range. After starting, the 1.62% gel is titrated on the pre-dose morning concentration at approximately 14 and 28 days, then periodically after that. The 2% solution uses a different rule entirely: a single draw 2 to 8 hours after application, at least 14 days after starting or after any dose change, targeting 300 to 1050 ng/dL. Reading one product's schedule onto the other produces a number that means nothing.

Monitoring carries more weight on this route than on injections precisely because absorption varies so widely from one man to the next. The AUA defines the therapeutic target as 450 to 600 ng/dL, the middle tertile of the reference range for most labs, and asks for a follow-up total testosterone after an appropriate interval to confirm the target was actually reached. With a weekly injection the trough is reasonably predictable from the dose. With a gel it is not, which is why the label builds two checks into the first month.

There is room to move in both directions. The 1.62% gel adjusts between 20.25 mg and 81 mg per day, and the 1% gel between 50 mg and 100 mg. The AUA notes that if one topical agent will not reach target even after dose adjustment, substituting a different topical agent is a viable strategy rather than an automatic move to injections. How you respond to one vehicle does not predict how you respond to another, and only a level tells you.

Real-world persistence on topical testosterone is poor, and the numbers are not close. A claims analysis of 15,435 men who started a topical testosterone gel found 34.7% still on medication at 6 months and 15.4% at 12 months, with no meaningful difference by age, diagnosis or starting dose. A separate commercially insured cohort of 3,184 topical initiators found 17% adherent at 12 months against a proportion-of-days-covered threshold of 80%, where adherence was associated with larger testosterone increases and fewer hypogonadism-associated conditions over the year.

The arithmetic explains much of it. A daily gel is 365 applications a year, each followed by hand washing, drying time and a clothing rule, plus a shower plan around any skin contact with your household. A weekly injection is roughly 52 events with no transfer precautions attached at all. Set against that, injections deliver a peak and trough cycle some men feel, they involve needles, and stopping them does not clear the drug within a few days. So the honest framing is a trade rather than an upgrade. Topicals give steady levels, fast reversibility and no needles, at the cost of a daily ritual and a risk that lands on your household instead of on you. Injections give fewer events and no transfer risk, at the cost of needles and slower washout.

Which tradeoff fits depends on who else lives in your home and how you actually behave day to day. Suitability is a clinician's call, and none of this is medical advice.

Baseline labs are not optional theater. The AUA asks for hemoglobin and hematocrit before offering testosterone therapy and rates that a strong recommendation at Grade A, advising that treatment be withheld if hematocrit already exceeds 50% until the cause is explained. On treatment, a hematocrit of 54% or higher warrants intervention, with dose adjustment as first-line management when the on-treatment testosterone is high. The same guideline asks for a PSA over age 40 before starting, to exclude a prostate cancer diagnosis rather than as routine screening.

Fertility is the part that gets skipped. Testosterone gel labels carry a warning on potential adverse effects on spermatogenesis, noting that exogenous administration of androgens may lead to azoospermia, and the AUA rates discussing the long-term impact on spermatogenesis with anyone interested in future fertility as a strong, Grade A recommendation. This is the mechanism doing what it is bound to do: suppressing your own gonadotropins suppresses sperm production. If children are anywhere in your plans, raise it before the first prescription rather than after.

Recovery data exists, although it comes from healthy volunteers on hormonal contraceptive regimens rather than from men on long-term replacement. An integrated analysis of 1,549 men across 30 studies found a median 3.4 months for sperm concentration to recover to 20 million per mL, with 67% recovered by 6 months, 90% by 12 months and effectively all by 24. Longer treatment and younger age slowed recovery. The AUA also notes that hCG, SERMs or aromatase inhibitors may be used when preserving fertility matters.

TRAVERSE is the trial the whole argument rests on, and it ran on exactly this route. 5,246 men aged 45 to 80 with existing or high cardiovascular risk and two fasting testosterone levels below 300 ng/dL were randomized to daily transdermal 1.62% testosterone gel, dose-adjusted to hold levels between 350 and 750 ng/dL, or to placebo gel. Mean treatment ran 21.7 months and mean follow-up 33.0 months. A primary event occurred in 7.0% on testosterone and 7.3% on placebo, hazard ratio 0.96 with a 95% confidence interval of 0.78 to 1.17.

Noninferior is not the same as harmless, and the secondary findings tend to get dropped from summaries. The same trial reported a higher incidence of atrial fibrillation, of acute kidney injury and of pulmonary embolism in the testosterone group. It also enrolled a specific population: middle-aged and older men with symptoms and two low morning levels, not men topping up a level that was already normal. The finding does not transfer outside those entry criteria, and the labels still carry a venous thromboembolism warning of their own.

The regulatory follow-through arrived in two steps. Class-wide labeling changes in early 2025 added the TRAVERSE result and a blood pressure warning, and current gel labels state that testosterone gel can increase blood pressure, that blood pressure should be measured periodically, and that it is not recommended in men with uncontrolled hypertension. Then in June 2026 FDA requested removal of the age-related hypogonadism limitation of use and revised prostate cancer and BPH safety information. Labels lag the request: gel labels posted through mid-2026 still carried the old limitation.

Public acquisition data gives you a floor to argue from. In the CMS National Average Drug Acquisition Cost file published on 2 September 2026, generic testosterone 1.62% gel pump ran $0.47172 per gram and testosterone 30 mg per 1.5 mL solution ran $0.56242 per mL. The 1% gel at 50 mg per 5 g is listed twice in that file: $0.40525 per gram across the five packet codes, which is the wider listing, and $0.74612 per gram across the two tube codes. At the label starting doses that is roughly $35 for the 1.62% gel, $51 for the solution, and either $61 or $112 for the 1% gel depending on which listing your pharmacy buys. NADAC is what a pharmacy pays to buy the drug. Nobody quotes you that number.

What you actually pay adds a dispensing fee, retail or telehealth markup, the consultation itself, and the lab draws the label requires twice in the first month. A compounded cream is often quoted below the branded gel, which is exactly why it gets offered, but that price gap buys a preparation with no FDA approval and no published pharmacokinetics behind its strength or vehicle. The AUA position is to prescribe a commercially manufactured product over a compounded one where that is possible.

On choosing where to get it, skip the marketing and check the process. Does the service require two separate morning testosterone levels before it will prescribe, as the label does. Does it schedule follow-up levels on the right timing rule for the product it actually dispenses. Does it order hemoglobin, hematocrit and, over 40, a PSA. Does anyone raise fertility before the first refill. Does transfer counseling happen as a real conversation rather than a checkbox on an intake form.